Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Strongbridge Bio Ord (NQ: SBBP)
2.770 USD  -0.050 (-1.77%)
Official Closing Price  /  Updated: 5:04 PM EDT, Jul 19, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 70,000
Open 2.770
Bid (Size) 2.700 (4)
Ask (Size) 4.730 (4)
Prev. Close 2.820
Today's Range 2.720 - 2.820
52wk Range 2.700 - 6.550
Shares Outstanding 35,335,026
Dividend Yield N/A
Performance
YTD
-37.61%
-37.61%
1 Month
-19.01%
-19.01%
3 Month
-38.44%
-38.44%
6 Month
-40.94%
-40.94%
1 Year
-45.15%
-45.15%
Top News
More News
Strongbridge Biopharma plc Announces New Employment Inducement Awards
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet... Read More
from GlobeNewswire News Releases
Strongbridge Biopharma plc Added to the Russell 3000® and Microcap® Indexes
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet... Read More
from GlobeNewswire News Releases
More News
Read More
Strongbridge Biopharma plc to Present at the 2019 JMP Securities Life Sciences Conference
from GlobeNewswire News Releases
Strongbridge Biopharma plc Strengthens Senior Leadership Team with Key Promotion and Appointment
from GlobeNewswire News Releases
Strongbridge Biopharma plc to Present at the Jefferies 2019 Global Healthcare Conference
from GlobeNewswire News Releases
Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Academy of Neurology Annual Meeting
from GlobeNewswire News Releases
Strongbridge Biopharma plc Reports First Quarter 2019 Financial Results and Provides Corporate Update
from GlobeNewswire News Releases
Strongbridge Biopharma plc Announces Presentation of New Secondary Endpoint Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 201
from GlobeNewswire News Releases
BIB's Holdings Could Mean 31% Gain Potential
category ETFs
from ETF Channel
Strongbridge Biopharma (SBBP) Q1 2019 Earnings Call Transcript
category Market News , SBBP
from Motley Fool
Strongbridge Biopharma plc (SBBP) Q1 2019 Earnings Call Transcript
category Market News , SBBP
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.